Astrazeneca (AZN) Net Cash Flow (2009 - 2026)

Astrazeneca's Net Cash Flow history runs 17 years deep, the most recent figure standing at -$1.5 billion for Q1 2026.

• In Q1 2026, Net Cash Flow rose 61.49% year-over-year to -$1.5 billion; the TTM figure through Mar 2026 stood at -$11.9 billion (up 23.37% YoY), while the FY2025 annual figure was $4.4 billion, up 11.04% from the prior year.
• Net Cash Flow was -$1.5 billion for Q1 2026 at Astrazeneca, up from -$4.7 billion in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of -$385.0 million in Q1 2024 to a low of -$5.6 billion in Q3 2024.
• Historically, Net Cash Flow has averaged -$3.0 billion across 5 years, with a median of -$3.3 billion in 2023.
• The sharpest annual moves came in 2024 and 2025: Net Cash Flow soared 88.25% in 2024, then tumbled 928.57% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$2.1 billion in 2022, then climbed by 2.67% to -$2.0 billion in 2023, then grew by 9.17% to -$1.9 billion in 2024, then tumbled by 155.29% to -$4.7 billion in 2025, then jumped by 67.75% to -$1.5 billion in 2026.
• The last three Net Cash Flow figures came in at -$1.5 billion (Q1 2026), -$4.7 billion (Q4 2025), and -$4.1 billion (Q3 2025), per Business Quant data.